Cladribine Tablets Receives Positive CHMP Opinion for Treatment of Relapsing Forms of Multiple Sclerosis - Seite 3

placebo-controlled study designed primarily to evaluate the safety
and tolerability of adding MAVENCLAD treatment to patients with
relapsing forms of MS, who have experienced breakthrough disease
while on established interferon-beta therapy.
- PREMIERE (Prospective Observational Long-term Safety Registry of
Multiple Sclerosis Patients Who Have Participated in Cladribine
Clinical Studies) study: interim long-term follow-up data from the
prospective registry, PREMIERE, to evaluate the safety and efficacy
of MAVENCLAD. The follow-up will consist of over 10,000 patient
years of exposure in total, with follow-up in some patients
exceeding eight years at completion.

About Multiple Sclerosis (MS)

Multiple sclerosis (MS) is an autoimmune, chronic and inflammatory
condition that affects the central nervous system (CNS) and is the
most common, non-traumatic, disabling neurological disease in young
adults. Relapsing remitting MS (RRMS) is the most common form of MS,
and around 85% of people with MS are diagnosed with this type.[1] The
exact cause of MS is unknown but it is thought that the body's immune
system attacks myelin, disrupting the information flow along the
nerves. There is currently no cure for MS, but treatments are
available to help slow the course of the disease.

All Merck Press Releases are distributed by e-mail at the same
time they become available on the Merck Website. Please go to
http://www.merckgroup.com/subscribe to register online, change your
selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare,
life science and performance materials. Around 50,000 employees work
to further develop technologies that improve and enhance life - from
biopharmaceutical therapies to treat cancer or multiple sclerosis,
cutting-edge systems for scientific research and production, to
liquid crystals for smartphones and LCD televisions. In 2016, Merck
generated sales of EUR 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and
chemical company. The founding family remains the majority owner of
the publicly listed corporate group. Merck holds the global rights to
the Merck name and brand. The only exceptions are the United States
and Canada, where the company operates as EMD Serono, MilliporeSigma
and EMD Performance Materials.

ots Originaltext: Merck KGaA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Gangolf Schrimpf
[phone]

Investor Relations
[phone].